Browsing Tag
Aurobindo Pharma Limited
8 posts
The factory is 60% empty. That may be exactly why Aurobindo Pharma (NSE: AUROPHARMA) wants it
Read how Aurobindo Pharma plans to turn Lannett’s underused US factory, ADHD portfolio and CDMO platform into its next growth engine as policy shifts.
Aurobindo Pharma clears FTC hurdle for $250m Lannett acquisition
Aurobindo Pharma clears the FTC hurdle for its $250 million Lannett deal. Explore divestitures, US expansion, integration risks and stock outlook.
Aurobindo Pharma stock slips as USFDA OAI classification tests investor confidence in #AUROPHARMA
Aurobindo Pharma faces USFDA OAI pressure at a Telangana unit. Find out why this matters for #AUROPHARMA investors today!
Who is really leading Indian pharma in 2026? The top 10 companies explained beyond the hype
Discover the top 10 pharma companies in India in 2026, who leads by revenue, reach, and strategy, and why the ranking is more complex than it looks.
Aurobindo Pharma (NSE: AUROPHARMA) shares slide after FDA flags compliance gaps at Telangana unit
Aurobindo Pharma shares fell after the US FDA flagged nine issues at a Telangana plant. Find out what it means for compliance, investors, and the stock outlook.
ACADIA Pharmaceuticals stock surges 26% after key patent win and robust Q1 results: What’s driving investor optimism?
Find out why ACADIA Pharmaceuticals stock soared 26% on May 16, 2025, after a favorable court ruling and strong earnings—plus what’s next for its CNS pipeline.
Aurobindo Pharma shatters expectations with record-breaking Q1 FY25 earnings
Aurobindo Pharma Limited, a key player in the global pharmaceuticals market, has once again demonstrated remarkable financial health…
Aurobindo Pharma secures FDA approval for Fingolimod Capsules
In a significant development for the pharmaceutical industry, Aurobindo Pharma Limited has announced receiving the final nod from…